NDA 017011 · Abbvie
Pred Forte
Prednisolone Acetate · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Jun 6, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
May 30, 1973
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,078
579 Phase 3, 236 recruiting
FAERS reports
11,227
5,507 serious, 577 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 3, 2026.
INDICATIONS AND USAGE Prednisolone acetate ophthalmic suspension 1% is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- PRED FORTE · PREDNISOLONE ACETATE 1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Prednisolone" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Steroids In caRdiac Surgery Trial (SIRS Trial)Pivotal-lookingStatus unknown
Population Health Research InstituteAcademic, hospital or other
NCT00427388 · 7,507 participants · Start Jun 2007 · Primary completion Feb 2014
Drug: Methylprednisolone · For: Cardiac Surgical Procedures; Cardiopulmonary Bypass; Systemic Inflammatory Response Syndrome
Sites: Hamilton, Canada
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19Pivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT05855395 · 5,815 participants (planned) · Start May 26, 2023 · Primary completion May 1, 2024
Drug: Glucocorticoid · For: COVID-19
Sites: Fuzhou, China; Quanzhou, China; Guangzhou, China · 15 sites in all
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 TrialPivotal-lookingRecruiting
Thomas EngstromAcademic, hospital or other
NCT07478003 · 5,204 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 20, 2031
Drug: Methylprednisolone 250 mg; NaCl (0,9%) · For: STEMI - ST Elevation Myocardial Infarction
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure1,267
- drug ineffective945
- eye pain791
- recalled product administered764
- off label use735
- no adverse event677
- eye irritation471
- vision blurred465
- headache382
- fatigue379
- ocular hyperaemia336
- diarrhoea301
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 71 |
| 2006 | 94 |
| 2007 | 109 |
| 2008 | 168 |
| 2009 | 111 |
| 2010 | 171 |
| 2011 | 148 |
| 2012 | 279 |
| 2013 | 200 |
| 2014 | 268 |
| 2015 | 405 |
| 2016 | 649 |
| 2017 | 439 |
| 2018 | 527 |
| 2019 | 604 |
| 2020 | 1,786 |
| 2021 | 562 |
| 2022 | 683 |
| 2023 | 757 |
| 2024 | 819 |
| 2025 | 933 |
| 2026 | 1,407 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pred Forte (Prednisolone Acetate)
2024 spending
$959K
Beneficiaries
1,718
3,969 claims
Per beneficiary
$558
$29.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,558,557 |
| 2021 | $1,365,453 |
| 2022 | $1,264,613 |
| 2023 | $1,189,393 |
| 2024 | $959,454 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prednisolone or pentoxifylline for alcoholic hepatitis.
Thursz MR, Richardson P, Allison M, et al. · N Engl J Med 2015 · Multicenter Study, Randomized Controlled Trial
- Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis.
Dahan E, El Ghazal N, Nakanishi H, et al. · J Asthma 2023 · Meta-Analysis, Systematic Review
- Cost-effectiveness of adrenocorticotropic hormone versus oral steroids for infantile spasms.
Sánchez Fernández I, Amengual-Gual M, Gaínza-Lein M, et al. · Epilepsia 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma: a systematic review and meta-analysis.
Wang H, Wang J, He X · J Asthma 2025 · Comparative Study, Meta-Analysis
- Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis.
Nguyen-Khac E, Thevenot T, Piquet MA, et al. · N Engl J Med 2011 · Comparative Study, Multicenter Study
- Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, et al. · Lancet 2012 · Comparative Study, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.